2022 thus far

by Katy Spink, DHC’s COO and Managing Partner

Welcome to the end of Q3’22, a time that feels like an excellent opportunity for an update on my thoughts from earlier this year regarding what 2022 could mean for cell and …

Dark Horse guidance – what’s next?

A conversation with Jacob Staudhammer (DHC Senior Consultant) and Christina Fuentes, Ph.D. (DHC Consultant)

Q: Hi, you two! So, before we jump into a discussion of next ideas, we should take a moment to look in the rearview mirror and …

Proposed DRAFT Guidance for FDA Consideration:

You are reading the beginning of the May 15th DHC Proposed Draft Guidance for FDA Consideration document itself. If you’re looking for the DHC press release on the same subject, click here. If you wish to reach out to us …

Anthony offers insights with Endpoints News

In early April, Endpoints News published “Avoiding Cell Therapy Manufacturing Gridlocks — a Do’s and Don’ts Guide,” in which guidance by our CEO, Anthony Davies, figured prominently. (One of his many quotes is above in the header on this page.)…

Will 2022 be the year that blew our minds?

by Katy Spink, DHC’s COO and Managing PartnerI’ve been thinking lately about what place this year, 2022, may ultimately hold in our memories. By this time next year when we have the benefit of some hindsight, will we be referring …

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.